BIO-FD&C Co.,Ltd.
Financials
Valuation Metrics
BIO-FD&C Co.,Ltd.'s Market Cap is ₩797B. At end of 2025 it was ₩1374B. Ranked #1369 of 2,405 in KR market (top 57%), #763 of 1,627 on KOSDAQ (top 47%), #151 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 79.74B KRW | KR#1,369/2,405 Sec#151/231 |
| Revenue | 19.53B KRW | KR#2,134/2,405 Sec#158/231 |
| Net Income | 6.39B KRW | KR#1,123/2,405 Sec#71/231 |
| Total Assets | 74.51B KRW | KR#1,970/2,405 Sec#163/231 |
| Net Assets | 70.96B KRW | KR#1,678/2,405 Sec#141/231 |
| Employees | 76 | KR#1,828/2,405 Sec#157/231 |
| Value | ||
| P/E | 12.47x | KR#995/2,405 Sec#57/231 |
| P/B | 1.12x | KR#1,616/2,405 Sec#105/231 |
| PEG | 4.60x | KR#815/2,405 Sec#51/231 |
| P/S | 4.08x | KR#2,107/2,405 Sec#141/231 |
| EV/EBITDA | 11.17x | KR#713/2,405 Sec#36/231 |
| FCF Yield | 7.91% | KR#722/2,405 Sec#35/231 |
| Profitability | ||
| ROE | 9.01% | KR#699/2,405 Sec#50/231 |
| ROA | 8.58% | KR#383/2,405 Sec#27/231 |
| Op. Margin | 31.22% | KR#55/2,405 Sec#13/231 |
| Revenue Growth | 12.64% | KR#772/2,405 Sec#76/231 |
| Earnings Growth | 2.71% | KR#809/2,405 Sec#51/231 |
| Financial Health | ||
| Debt Ratio | 5.00% | KR#35/2,405 Sec#11/231 |
| Total Debt | 100.0M KRW | KR#2,024/2,405 Sec#188/231 |
| FCF | 6.30B KRW | KR#842/2,405 Sec#56/231 |
| Cash | 11.73B KRW | KR#1,599/2,405 Sec#135/231 |
| Current Ratio | 19.09x | KR#27/2,405 Sec#12/231 |
| Net Debt/EBITDA | -1.91x | KR#246/2,405 Sec#11/231 |
| Performance | ||
| 1Y Return | -44.26% | KR#1,795/2,405 Sec#152/231 |
| 1M Return | -6.71% | KR#871/2,405 Sec#82/231 |
| From 52W High | -48.28% | KR#1,089/2,405 Sec#79/231 |
| 1Y MDD | -58.59% | KR#1,354/2,405 Sec#113/231 |
| Trading | ||
| Volume | 5,013 shares | KR#2,097/2,405 Sec#212/231 |
| Trading Value | 45.5M KRW | KR#1,774/2,405 Sec#189/231 |
| Foreign Own. | 10.98% | KR#442/2,405 Sec#36/231 |
| Per Share | ||
| EPS | 735 KRW | KR#850/2,405 Sec#61/231 |
| BPS | 8,160 KRW | KR#1,124/2,405 Sec#81/231 |
Company Info
Established in 2005, the company conducts research, development, and production of active and pharmacological substances based on its plant cell platform technology. With 18 years of accumulated expertise, it boasts the world's largest plant cell library and has established a Plant Cell Banking system for cryopreserving over 120 species. Utilizing the world's first SMART-RC² new technology with high-frequency waveform application, the company's mass culture process supplies various clients, realizing steady sales growth. BIOFD&C is headquartered in Yeonsu-gu, Incheon.